

Long Noncoding RNA UCA1 Targets miR-582-5p and Contributes to the Progression and Drug Resistance of Bladder Cancer Cells Through ATG7-Mediated Autophagy Inhibition [Retraction]

Wu J, Li W, Ning J, Yu W, Rao T, Cheng F. *Onco Targets Ther.* 2019;12:495–508.

At the authors request, the Editor and Publisher of the journal *OncoTargets and Therapy* have retracted the published article.

Following publication of the article, the authors raised concerns about the duplication of images from Figure 6 with those from unrelated articles. Specifically,

- Images for Figure 6F, shRNA scramble, PCNA and UCA1 shRNA, Ki67, have been duplicated with images for Figure 4E, MCCK1+TMZ, Caspase-3 and Figure 5E, IM+Tan, Ki67, from Liu T, Li A, Xu Y, Xin Y. MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo. *Cancer Med.* 2019;8:751–760. <https://doi.org/10.1002/cam4.1951> and Teng Z, Xu S, Lei Q. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB-152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway [Retracted]. *Oncology Reports.* 2020;43:503-515. <https://doi.org/10.3892/or.2019.7453>, respectively.

The corresponding author was cooperative and responded to our queries but was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and the Publisher and Editor agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>